[{"id":"588df3d5-5d65-433f-861f-c02c9919175e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00952692","created_at":"2021-01-18T03:42:20.748Z","updated_at":"2025-02-25T13:15:07.953Z","phase":"Phase 1/2","brief_title":"Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer","source_id_and_acronym":"NCT00952692","lead_sponsor":"Michael Morse, MD","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • lapatinib • dHER2+AS15"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 07/01/2009","start_date":" 07/01/2009","primary_txt":" Primary completion: 07/01/2011","primary_completion_date":" 07/01/2011","study_txt":" Completion: 04/01/2012","study_completion_date":" 04/01/2012","last_update_posted":"2021-12-20"},{"id":"c6a1ca68-df2a-4ec7-910d-b0b25f8aca76","acronym":"","url":"https://clinicaltrials.gov/study/NCT00140738","created_at":"2021-01-18T00:28:49.881Z","updated_at":"2024-07-02T16:36:52.060Z","phase":"Phase 1/2","brief_title":"Safety and Immunogenicity Study of the New dHER2 Vaccine to Treat HER2-positive Metastatic Breast Cancer","source_id_and_acronym":"NCT00140738","lead_sponsor":"GlaxoSmithKline","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dHER2+AS15"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 03/10/2005","start_date":" 03/10/2005","primary_txt":" Primary completion: 09/29/2008","primary_completion_date":" 09/29/2008","study_txt":" Completion: 09/29/2009","study_completion_date":" 09/29/2009","last_update_posted":"2019-12-27"},{"id":"9571bff7-45a4-4092-9335-e996a04d4d27","acronym":"","url":"https://clinicaltrials.gov/study/NCT00058526","created_at":"2021-01-18T00:07:31.892Z","updated_at":"2024-07-02T16:37:22.221Z","phase":"Phase 1","brief_title":"A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer","source_id_and_acronym":"NCT00058526","lead_sponsor":"GlaxoSmithKline","biomarkers":" HER-2 • IFNG • CD4 • IL5","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2 • IFNG • CD4 • IL5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dHER2+AS15"],"overall_status":"Completed","enrollment":" Enrollment 61","initiation":"Initiation: 03/20/2003","start_date":" 03/20/2003","primary_txt":" Primary completion: 09/06/2006","primary_completion_date":" 09/06/2006","study_txt":" Completion: 09/06/2006","study_completion_date":" 09/06/2006","last_update_posted":"2017-05-15"}]